Effectively Responding to FDA Form 483

Organizations that receive Form 483 upon completion of an inspection and are ill- equipped to respond may face a warning letter from the U.S. Food and Drug Administration (FDA) and, in severe cases, be prohibited from manufacturing and selling their products. That said, there are a number of best practices medical device manufacturers can employ to respond to Form 483 to mitigate the chances that the observations escalate to an FDA warning letter.

The Best Defense Is a Good Offense

Time and again, we encounter organizations that believe that receiving a Form 483 upon inspection completion is a forgone conclusion. This is inaccurate. Companies with comprehensive internal audit processes that are effective at identifying the existence of or potential for non-compliance tend to emerge from an inspection with no observations noted. That, of course, is the desired goal with every inspection. But what if an organization, despite its best efforts, still receives a 483?

There are two courses of action to consider.

Course #1: Provide Effective Annotation

Often, companies can preclude or reverse the decision of the Form 483 by providing quality annotation. Before the inspector leaves the premises, organizations have the opportunity to pause, consider the observations, and respond. A savvy organization with an effective internal audit process typically can preclude the Form 483 from going any further by providing an annotation for each observation. Annotations that are well-reasoned, complete, timely and include an action plan to achieve immediate, short-term, and long-term remediation often lead inspectors to dismiss the observation from the Form 483 right then and there, ensuring it’s never filed and eliminating the potential that the observation and, ultimately, the Form 483 could develop into a warning letter.

If the annotation does not satisfy the inspector, the Form 483 will be filed, and organizations will need to develop a well-reasoned, complete, and timely response to the observations noted on the Form 483.

Course #2: Responding to the Form 483

Submitting a well-reasoned, complete, and timely Form 483 response demonstrates to the FDA that the medical device manufacturer understands and acknowledges the observations and illustrates its commitment to correct those observations. It also establishes credibility with the FDA and may mitigate an FDA compliance decision for further action.

According to the FDA, an effective Form 483 response should:

• Include a commitment/statement from senior leadership;
• Address each observation separately;
• Note whether the company agrees or disagrees with the observation;
• Provide corrective action accomplished and/or planned. Here it’s important to be specific, complete, and realistic—companies must ensure that they deliver what they promise;
• Provide time frames for correction;
• Provide a method of verifying and/or monitoring corrections;
• Consider submitting documentation of corrections where reasonable and feasible; and
• Be timely.

* * * 
No medical device manufacturer wants to receive a Form 483 or—worse—a warning letter from the FDA. The key toresolving the situation is timely remediation. Submitting a thorough, reasonable response that provides a realistic action plan with specific time frames for correction is the best way to avoid the worst-case scenario and ensure that business as usual can continue.

Phillip Brown is the medical device practice leader in Plante Moran’s management consulting group, with more than 20 years of manufacturing,operations, and engineering experience in the medical device industry. Brown has performed product and process transfers through a variety of business relationships including OEM consolidation, OEM outsource domestically and internationally through contract and toll manufacturing, OEM in-sourcing, shelter, and the establishment of offshore principal/subsidiary manufacturing. Consulting firm Plante Moran is based in Southfield, Mich.